Exciting Investor Conferences by Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is gearing up for a series of significant investor conferences. This presents a unique opportunity for investors and interested parties to gain insights into the company’s current initiatives and future plans in the biotech space.
Upcoming Webcast Details
The management team of Regeneron will be participating in important conferences, starting with the Jefferies London Healthcare Conference at 11:00 a.m. BST. Following closely, the Piper Sandler 36th Annual Healthcare Conference is set for 9:30 a.m. ET. These webcasts are accessible through the "Investors & Media" section on Regeneron's official website. Not only will participants gain real-time insights during these sessions, but replays and transcripts will also be available for up to 30 days. This ensures that valuable information is accessible for those unable to attend live.
About Regeneron Pharmaceuticals
Regeneron (NASDAQ: REGN) stands as a leader in the biotechnology sector, driven by a mission to develop life-transforming medicines tailored for individuals grappling with severe diseases. Established by physician-scientists, Regeneron's consistency in turning scientific breakthroughs into real-world applications has led to a robust portfolio of approved treatments alongside promising product candidates that are often developed within their own labs.
Innovative Approaches to Drug Development
The company’s extensive pipeline addresses a wide array of health challenges, including eye diseases, allergic conditions, cancers, and rare diseases. Utilizing proprietary technologies, such as the VelociSuite platform, Regeneron is at the forefront of scientific advancement, focusing on the production of optimized and fully human antibodies and bispecific antibodies. This commitment to innovation doesn’t stop there—through the Regeneron Genetics Center, the company harnesses genetic data to identify novel drug targets and approaches, with the goal of revolutionizing treatment possibilities.
Company Commitment and Future Outlook
As Regeneron continues to push the envelope in scientific discovery, the commitment to patient care remains paramount. They focus intensely on utilizing data-powered insights to refine drug development strategies. In a landscape that is continuously changing, Regeneron remains dedicated to shaping the future of healthcare with groundbreaking therapies and strong research endeavors.
Staying Connected with Regeneron
Stakeholders and interested parties can easily find additional information about Regeneron's ongoing projects and achievements by visiting their official website. They can also follow the company on popular social media platforms like LinkedIn, Instagram, Facebook, and Twitter for the latest updates and news.
Contacting Regeneron
For direct inquiries, investors can reach out to the Investor Relations department. Ryan Crowe is available at 914.847.8790. Additionally, they can connect via email for further information regarding their investor relations.
Frequently Asked Questions
What conferences will Regeneron be participating in?
Regeneron will be participating in the Jefferies London Healthcare Conference and the Piper Sandler 36th Annual Healthcare Conference.
Where can I access the webcast of these conferences?
The webcasts can be accessed on Regeneron’s "Investors & Media" webpage, with replays available for 30 days.
What is Regeneron known for?
Regeneron is known for inventing and developing advanced medicines for serious diseases, utilizing cutting-edge biotechnology and research methodologies.
How does Regeneron contribute to genetic medicine?
Through the Regeneron Genetics Center, the company employs genetic insights to identify innovative therapeutic targets, advancing the field of genetic medicine.
Who can I contact for investor-related questions at Regeneron?
For inquiries, you can contact Ryan Crowe from the Investor Relations team at 914.847.8790 or via email.